Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.8% on Analyst Downgrade

Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) shares dropped 6.8% during trading on Tuesday after Citigroup lowered their price target on the stock from $43.00 to $42.00. Citigroup currently has a buy rating on the stock. Summit Therapeutics traded as low as $10.82 and last traded at $11.0190. Approximately 2,758,735 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 4,719,630 shares. The stock had previously closed at $11.82.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. Sanford C. Bernstein restated a “market perform” rating on shares of Summit Therapeutics in a research report on Monday, October 5th. Barclays cut their target price on Summit Therapeutics from $20.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Monday. Summit Redstone set a $25.00 target price on Summit Therapeutics in a research report on Wednesday, September 9th. Finally, Stifel Nicolaus lowered their price target on Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $28.38.

Check Out Our Latest Analysis on Summit Therapeutics

Latest Summit Therapeutics News

Investors following SMMT have been watching these news items:

  • Neutral Sentiment: Barclays lowered its target to $18 and kept an Equal Weight rating. The divergent analyst outlooks offer limited reassurance against the regulatory setback. Barclays rating
  • Negative Sentiment: The FDA issued a Complete Response Letter (CRL) for ivonescimab, citing insufficient overall-survival evidence despite positive progression-free-survival results. The drug is not approved, and the decision raises uncertainty about what additional evidence or clinical work may be needed before a resubmission. Reuters report on FDA decision
  • Negative Sentiment: The FDA decision drove SMMT to a new 52-week low after several sessions of declines, reflecting investors’ reassessment of the drug’s approval prospects and near-term commercial potential. Report on Summit’s 52-week low

Institutional Trading of Summit Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Summit Therapeutics in the second quarter worth about $138,838,000. Bellevue Group AG lifted its position in Summit Therapeutics by 13,733.9% in the third quarter. Bellevue Group AG now owns 2,113,681 shares of the company’s stock worth $35,742,000 after buying an additional 2,098,402 shares during the last quarter. Candriam S.C.A. boosted its stake in shares of Summit Therapeutics by 212.3% during the 3rd quarter. Candriam S.C.A. now owns 1,662,969 shares of the company’s stock worth $28,224,000 after purchasing an additional 1,130,537 shares during the period. Bank of America Corp DE purchased a new position in shares of Summit Therapeutics during the second quarter valued at approximately $12,603,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Summit Therapeutics by 34.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 592,810 shares of the company’s stock valued at $11,240,000 after acquiring an additional 151,857 shares during the period. 4.61% of the stock is currently owned by institutional investors.

Summit Therapeutics Stock Down 6.8%

The stock has a market capitalization of $8.81 billion, a PE ratio of -10.34 and a beta of -1.49. The stock’s 50 day moving average price is $16.30 and its 200-day moving average price is $16.12.

About Summit Therapeutics

(Get Free Report)

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.

Further Reading

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.